Compliance · Inspection readinessUpdated September 28, 2026

FDA inspection checklist for clinical trial data

When an FDA investigator arrives, the questions about your data are predictable: can you show who entered it, who changed it and why, who signed it, and that it matches the source. This checklist covers what gets reviewed and how to have the answers ready.

  • Site and sponsor checklists
  • Audit trail and e-signature evidence
  • Built from BIMO focus areas

Free sandbox · No credit card · 21 CFR Part 11 aligned

Inspection readiness · Study ABC-201

Ready

9 / 12

Open queries

4

Days to visit

6

  • Audit trail export for all subjectsExported
  • Signed consent for every enrolled subject
  • Delegation log current
  • Eligibility signed before randomisation
  • SAEs reported within timelines1 late
  • Protocol deviations reviewed
  • Training records for new staff
Evidence exported, not reconstructed

Key points

  • FDA's Bioresearch Monitoring (BIMO) program inspects clinical investigators, sponsors, CROs and monitors, and IRBs. Inspections may be routine surveillance, for-cause, or linked to a marketing application such as an NDA or BLA.
  • Data-related findings recorded on Form FDA 483 typically involve records that are not adequate or accurate, protocol deviations, consent problems, and missing or late safety reporting.
  • Inspectors verify that data in the case report forms matches source documents, and that every change is attributable, dated and explained.
  • For electronic systems they look at access control, audit trails, electronic signatures and evidence that the system was fit for purpose, the expectations behind 21 CFR Part 11.
  • The best preparation is a study run inspection-ready from day one, where evidence is exported, not reconstructed.

The inspection

What an FDA BIMO inspection looks at

FDA conducts clinical trial inspections under compliance programs that describe what investigators should review. For clinical investigators the focus is on whether the investigator conducted the study according to the protocol and regulations, protected participants' rights and welfare, and produced records that accurately reflect what happened. Sponsor and CRO inspections focus on oversight: monitoring, safety reporting, data management and vendor control.

In both cases data integrity sits at the centre. An inspector will select participants and trace their data from source documents through the case report form to the submitted datasets, looking for discrepancies, unexplained changes and gaps. The questions follow the ALCOA+ principles: is each record attributable, legible, contemporaneous, original and accurate, and also complete, consistent, enduring and available? The ALCOA+ data integrity checklist goes through each principle.

Common data-related observations

Inadequate or inaccurate case histories are among the most frequent clinical investigator findings: CRF entries that do not match source, missing source documents, or changes without explanation. Close behind are failures to follow the protocol (including enrolling ineligible participants), consent that was not obtained or documented correctly, and adverse events not reported as required. Each maps to something your data system can make visible before the inspector finds it.

Weight changed 68.0 to 68.5 kg

Site coordinator · Reason: Transcription error

9f2c…a71e

Query Q-0014 answered on Weight

Site coordinator · Reason: Source checked

4b8d…c203

Vital signs form locked

Data manager · Reason: Visit cleaned

e61a…58f0
Verify chain Intact

Site checklist

What to have ready at the investigator site

AreaWhat the inspector checksEvidence to have ready
Informed consentEvery participant consented before any study procedure, with the approved versionSigned consent records with timestamps and version; re-consent after amendments
EligibilityEach enrolled participant met every criterionEligibility forms with investigator sign-off, supporting source values
Source vs CRFCRF values match source documentsSDV records, query history, source document locations
Data changesEvery change attributable, dated and explainedField-level audit trail with old value, new value, user, time and reason
Adverse eventsAll AEs recorded, SAEs reported on timeAE log, SAE timelines, investigator sign-off
Protocol deviationsDeviations identified, documented and reportedDeviation log with assessments
Delegation and trainingOnly trained, delegated staff performed study tasksDelegation log, training acknowledgements
Investigational productReceipt, storage, dispensing and return reconcileAccountability records

System checklist

Questions about the electronic data system

Sponsors and sites should be able to answer these about any system that holds trial data. Capture's answers are shown where they are product features; procedures remain your responsibility.

QuestionWhat a good answer showsIn Capture
Who can access the data?Role-based access, individual accounts, access reviewsRole matrix per study and site; site staff see only assigned sites
Can changes be traced?Complete, tamper-evident audit trailOne audit row per changed field, SHA-256 hash chain with a verify check
Can the audit trail be altered?No edits or deletesAppend-only; updates and deletes blocked in the database
Are signatures valid?Re-authentication, meaning, link to the recordPassword re-entry verified on the server, meaning stored with each signature
Are timestamps reliable?Server-set, not user-setSet by the server, not the browser
Is deleted data recoverable?No hard deletes of clinical dataSoft deletes kept in the audit history
Was the system fit for purpose?Validation evidence for intended useYour validation, supported by vendor documentation; see CSV guide

Evidence on demand

Export the evidence instead of assembling it

The difference between a stressful inspection and a routine one is often how quickly records can be produced. In Capture the audit trail is always exportable, with readable descriptions and filters by category, user, participant and date, and every data export is itself logged with the user, time, filters and row count.

  • Audit trail filtered by participant for the subjects the inspector selects.
  • Signed consent exported as PDF with embedded signature data and audit trail.
  • Query history and SDV status per field.
  • Append-only export log for every dataset produced.
Audit-ready clinical trial data
Data and exports
Clinical data (codes + labels)Data dictionaryAnnotated CRFSAS transport (XPT)E2B safetyAudit trail
SUBJECGPERF_CODEECGPERF_LABEL
01-001YYes
01-002NDNot done

See what an inspector would see

Change a value, sign a form and export the audit trail in the free sandbox.

See an audit-ready study free

Preparation

How to prepare in the weeks before an inspection

Notice periods vary, and for-cause inspections may come with little warning, so the most reliable preparation is continuous. Still, a structured review in the weeks before a known inspection catches the issues most likely to become observations.

Run your own trace

Pick a handful of participants, including any with SAEs, deviations or re-consent, and trace their data from source through the eCRF to the latest export. Every discrepancy you find is one the inspector will not.

Close what can be closed

Resolve open queries, complete outstanding SDV on critical fields, and make sure investigator sign-offs are current. Do not backdate or recreate documents: an explained gap is far better than an unexplained correction, and the audit trail will show when things were done.

Prepare people as well as records

Identify who will answer questions about the data system, who can run exports during the inspection, and who owns each area of the checklist. Practise pulling an audit trail for a specific participant and field.

FAQ

Questions teams ask before they switch

Something not covered here? Ask us directly.

What is an FDA BIMO inspection?

An inspection under FDA's Bioresearch Monitoring program, which covers clinical investigators, sponsors, CROs and monitors, IRBs and others, to verify data integrity and participant protection.

What is a Form FDA 483?

The form on which FDA investigators record inspectional observations at the end of an inspection. It lists conditions the investigator believes may violate regulations.

What data problems are most commonly cited?

Inadequate or inaccurate records, protocol deviations such as enrolling ineligible participants, informed consent problems and failures in adverse event reporting.

What will an inspector ask about our EDC?

Who has access, how changes are tracked, whether the audit trail can be altered, how electronic signatures work, how timestamps are set, and how the system was validated for its intended use.

Can Capture export the audit trail for an inspector?

Yes. The audit trail is always exportable and can be filtered by participant, user, category and date.

Does using a Part 11-aligned system make us inspection-ready?

It provides the technical controls. Inspection readiness also depends on your procedures, training, validation and how the study was actually conducted.

Be inspection-ready every day

Tamper-evident audit trail, verified signatures and exports on demand. Free sandbox.

See an audit-ready study free